NASDAQ:PTCT - PTC Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$45.37 -1.82 (-3.86 %)
(As of 09/20/2018 08:17 AM ET)
Previous Close$47.19
Today's Range$45.01 - $47.4850
52-Week Range$14.56 - $52.95
Volume847,558 shs
Average Volume962,912 shs
Market Capitalization$2.37 billion
P/E Ratio-22.46
Dividend YieldN/A
PTC Therapeutics logoPTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy. It is developing Translarna, which is in Phase II clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 for the treatment of patients with spinal muscular atrophy, as well as PTC596, an orally bioavailable and potent small molecule that has completed Phase I study, which targets solid tumor cell populations by reducing the activity and amount of BMI1. The company has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and research collaboration with CHDI Foundation, Inc. to discover and develop small-molecule therapeutics for Huntington's disease. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.

Receive PTCT News and Ratings via Email

Sign-up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.55
Current Ratio4.34
Quick Ratio4.18


Trailing P/E Ratio-22.46
Forward P/E Ratio-30.66
P/E GrowthN/A

Sales & Book Value

Annual Sales$194.39 million
Price / Sales11.73
Cash FlowN/A
Price / CashN/A
Book Value$3.77 per share
Price / Book12.03


EPS (Most Recent Fiscal Year)($2.02)
Net Income$-79,000,000.00
Net Margins-25.03%
Return on Equity-27.41%
Return on Assets-11.96%


Outstanding Shares50,260,000
Market Cap$2.37 billion

PTC Therapeutics (NASDAQ:PTCT) Frequently Asked Questions

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.15. The biopharmaceutical company earned $68.74 million during the quarter, compared to the consensus estimate of $69.83 million. PTC Therapeutics had a negative return on equity of 27.41% and a negative net margin of 25.03%. View PTC Therapeutics' Earnings History.

When is PTC Therapeutics' next earnings date?

PTC Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for PTC Therapeutics.

What price target have analysts set for PTCT?

8 brokerages have issued 12-month target prices for PTC Therapeutics' shares. Their forecasts range from $11.00 to $53.00. On average, they anticipate PTC Therapeutics' stock price to reach $33.8333 in the next twelve months. This suggests that the stock has a possible downside of 25.4%. View Analyst Price Targets for PTC Therapeutics.

What is the consensus analysts' recommendation for PTC Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PTC Therapeutics.

What are Wall Street analysts saying about PTC Therapeutics stock?

Here are some recent quotes from research analysts about PTC Therapeutics stock:
  • 1. William Blair analysts commented, "CX-072 Data at ASCO. CTMX’s lead proprietary program, CX-072, will have first in human data at ASCO, both monotherapy (A") arm and combination with ipilimumab (B") arm. Since these data are early and not complete data sets, high levels of response rates may not be likely, but we think activity, even a modest level, could represent upside for the shares given that this is first in human data. We think a key proof of the technology will be measurement of systemically active versus intact" Probody CX-072." (5/10/2018)
  • 2. According to Zacks Investment Research, "PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States. " (5/9/2018)
  • 3. Cowen Inc analysts commented, "Yesterday Clearside announced the completion of enrollment in the TYBEE study in." (10/25/2017)

Who are some of PTC Therapeutics' key competitors?

Who are PTC Therapeutics' key executives?

PTC Therapeutics' management team includes the folowing people:
  • Dr. Stuart W. Peltz, Co-Founder, CEO & Exec. Director (Age 58)
  • Dr. Allan Steven Jacobson, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 72)
  • Ms. Christine Utter, Principal Financial Officer & Treasurer (Age 40)
  • Mr. Marcio Souza, Chief Operating Officer (Age 39)
  • Dr. Neil Almstead, Exec. VP of Research, Pharmaceutical Operations & Technology (Age 51)

Has PTC Therapeutics been receiving favorable news coverage?

Press coverage about PTCT stock has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. PTC Therapeutics earned a news and rumor sentiment score of 0.18 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View Recent Headlines for PTC Therapeutics.

Who are PTC Therapeutics' major shareholders?

PTC Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include RTW Investments LP (8.72%), BlackRock Inc. (7.43%), Scopia Capital Management LP (4.93%), Boxer Capital LLC (4.07%), FMR LLC (2.59%) and Northern Trust Corp (1.47%). Company insiders that own PTC Therapeutics stock include Christine Marie Utter, Dawn Svoronos, Marcio Souza, Neil Gregory Almstead and Stuart Walter Peltz. View Institutional Ownership Trends for PTC Therapeutics.

Which major investors are selling PTC Therapeutics stock?

PTCT stock was sold by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Russell Investments Group Ltd., Boxer Capital LLC, Frontier Capital Management Co. LLC, Millennium Management LLC, Connor Clark & Lunn Investment Management Ltd., Spark Investment Management LLC and Asymmetry Capital Management L.P.. Company insiders that have sold PTC Therapeutics company stock in the last year include Christine Marie Utter, Marcio Souza, Neil Gregory Almstead and Stuart Walter Peltz. View Insider Buying and Selling for PTC Therapeutics.

Which major investors are buying PTC Therapeutics stock?

PTCT stock was acquired by a variety of institutional investors in the last quarter, including PointState Capital LP, FMR LLC, BlackRock Inc., First Trust Advisors LP, Schwab Charles Investment Management Inc., Northern Trust Corp, Trexquant Investment LP and ClariVest Asset Management LLC. View Insider Buying and Selling for PTC Therapeutics.

How do I buy shares of PTC Therapeutics?

Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PTC Therapeutics' stock price today?

One share of PTCT stock can currently be purchased for approximately $45.37.

How big of a company is PTC Therapeutics?

PTC Therapeutics has a market capitalization of $2.37 billion and generates $194.39 million in revenue each year. The biopharmaceutical company earns $-79,000,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. PTC Therapeutics employs 373 workers across the globe.

How can I contact PTC Therapeutics?

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected]

MarketBeat Community Rating for PTC Therapeutics (NASDAQ PTCT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  399 (Vote Outperform)
Underperform Votes:  370 (Vote Underperform)
Total Votes:  769
MarketBeat's community ratings are surveys of what our community members think about PTC Therapeutics and other stocks. Vote "Outperform" if you believe PTCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel